RSH 2.70% 3.6¢ respiri limited

Ann: CEO Operational Review, page-10

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,973 Posts.
    lightbulb Created with Sketch. 82

    I think you should read up on what it is like to live with asthma. Then you will understand the need for Respiri management tool which will use a smartphone to record datA on a daily basis using a hand held device.which monitors wheeze.

    Resap is a tool that can diagnose what type of respiratory disease the person has when they present with a problem. They will cough into smart phone and a diagnosis is made. Is it pneumonia or is it a myriad of other problems including asthma? If asthma then they will require the Respri asthma management tool which will help them to manage their condition and hopefully reduce severe attacks.

    Therefore imo they are not competitors but will be complementary.

    Even if they were competing why try and make an issue here? Competition is healthy and is a natural part of business today.
    Last edited by birdchirp: 07/08/18
 
watchlist Created with Sketch. Add RSH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.